Overview

• PLT012, a humanized antibody targeting the lipid transporter CD36, has demonstrated preclinical efficacy in reversing immune suppression in liver cancer and colon metastases.
• The therapy restores CD8+ T-cell function, reduces suppressive immune cells, and reshapes the tumor immune landscape in fat-rich microenvironments.
• Preclinical studies show that PLT012 synergizes with existing checkpoint inhibitors, enhancing anti-tumor responses in resistant cancer models.
• Safety evaluations in mice and non-human primates confirm a favorable profile, addressing concerns about CD36's broad expression in the body.
• Having received FDA orphan drug designation, PLT012 is now set for first-in-human clinical trials by a dedicated spin-off company.